Today: 30 April 2026
Oracle stock edges up after Oppenheimer upgrade; what ORCL investors watch next
25 February 2026
2 mins read

Oracle stock edges up after Oppenheimer upgrade; what ORCL investors watch next

New York, February 25, 2026, 17:11 ET — Trading after the bell.

  • Oracle shares closed up and showed a small gain in after-hours trading.
  • Oppenheimer lifted Oracle to Outperform, bumping the price target up to $185.
  • Attention shifts to how Oracle will bankroll its cloud expansion, and what the upcoming earnings release might reveal.

Oracle shares edged higher late Wednesday, picking up after Oppenheimer boosted its rating on the software maker. The firm pointed to the recent selloff, saying it’s sharpened the setup for investors.

Oracle’s call arrives at a tricky juncture, with the market still wrestling with how to value a company ramping up spend to capture cloud and AI growth, while investors eye the balance sheet with some anxiety.

Cloud expansion alone isn’t the story anymore. Traders are focused on whether a handful of big clients will actually deliver reliable cash flow—quickly enough to cover the heavy funding burden.

Oracle ended regular trading with a 1.2% gain at $147.89, and ticked up another 0.2% after hours to $148.25. Shares seesawed from $147.35 to $153.26 during the day, with roughly 24.3 million shares changing hands. The stock tumbled 4.6% on Monday, then clawed back 3.4% Tuesday. The Nasdaq wrapped up about 1.3% higher.

Oppenheimer bumped Oracle up to Outperform from Perform, assigning a $185 price target. “While our call may be early … we see a favorable risk/reward after the stock’s multiples have been cut by more than half since September,” analyst Brian Schwartz said, pointing to valuation metrics like price-to-earnings. He called Oracle a “strong EPS compounder”—EPS stands for earnings per share—and maintained that the base case still lines up with earnings doubling by fiscal 2030. Schwartz also tagged Oracle as a “show me” story, saying the company still needs to execute to shift sentiment. Investing.com

The upgrade hasn’t put the main argument to rest. Oracle wants investors to overlook rising costs and instead pay attention to what it calls contracted demand stacking up in its cloud infrastructure segment.

Earlier this month, Oracle laid out plans to raise between $45 billion and $50 billion in gross proceeds in calendar 2026, aiming to fund Oracle Cloud Infrastructure buildouts for major clients such as AMD, Meta, Nvidia, OpenAI, TikTok and xAI. About half of that is slated to come via equity and equity-linked offerings—including a fresh at-the-market program that could reach $20 billion, letting the firm gradually sell shares. The balance would be raised through a single, investment-grade bond transaction. Oracle also pointed to a number of risks, from when and whether customers follow through on purchases or commitments, to potential delays or mishaps in constructing new data centers.

Oracle wrapped up a $25 billion notes sale on Feb. 4, according to a filing. The company intends to use the funds for general corporate needs—potentially capital expenditures, debt repayment, and other purposes.

Oracle, in a Feb. 2 filing, disclosed it had signed an underwriting agreement for the sale of 100 million depositary shares tied to a 6.50% mandatory convertible preferred stock. The deal wrapped up on Feb. 5.

Still, there’s not much margin for error. A dip in cloud demand, hesitancy from major clients, or harsher hits from financing costs and dilution—any of these could sap the stock’s momentum fast, putting the balance sheet right back in focus.

Oracle’s next earnings drop is set for March 9. Investors are zeroed in on signals about cloud demand, how fast customers are spending—and crucially, when that spend turns into cash flow.

Stock Market Today

  • Why Investors Are Focused on Vaidya Sane Ayurved Laboratories (NSE:MADHAVBAUG) Amid Growth and High Insider Ownership
    April 29, 2026, 10:29 PM EDT. Vaidya Sane Ayurved Laboratories (NSE:MADHAVBAUG) has attracted investor attention due to its strong financial performance and insider alignment. The company has delivered a compound annual EPS growth of 19% over the past three years, signaling sustained earnings momentum. Revenue growth and an improved EBIT margin, up by 6.6 percentage points to 11%, underscore operational strength. With insiders owning 78% of the firm, alignment between management and shareholders is notably high, reducing agency risk. Valued at ₹2.5 billion, the company appeals to investors favoring profitable, growing firms over speculative ventures without revenue or profit history. This combination of growth, profitability, and insider confidence makes Vaidya Sane a compelling pick in the Ayurvedic healthcare sector.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Netflix stock jumps 6% on Warner bid twist — what investors watch next
Previous Story

Netflix stock jumps 6% on Warner bid twist — what investors watch next

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus
Next Story

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Go toTop